Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Fostroxacitabine Bralpamide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Medivir's Fostrox + Lenvima Shows Promise In Liver Cancer
    Medivir's Fostrox + Lenvima Shows Promise In Liver Cancer

    16 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/medivirs-fostrox--lenvima-confirm-promise-of-improved-outcomes-in-advanced-liver-cancer-detailed-and-mature-data-presented-at-esmo-302248817.html

    PR NEWSWIRE
    16 Sep 2024
    Share Share
    Fostrox + Lenvima® holds promise of greatly improved outcomes
    Fostrox + Lenvima® holds promise of greatly improved outcomes

    27 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fostrox--lenvima-holds-promise-of-greatly-improved-outcomes-for-advanced-liver-cancer-patients-reveals-new-data-from-medivir-at-esmo-gi-302184220.html

    PR NEWSWIRE
    27 Jun 2024
    Share Share
    Medivir Selects CRO For Phase 2b HCC Study With Fostrox + Lenvima
    Medivir Selects CRO For Phase 2b HCC Study With Fostrox + Lenvima

    19 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/medivir-selects-global-cro-partner-for-upcoming-phase-2b-study-in-hcc-with-fostrox--lenvima-and-initiates-study-feasibility-302176636.html

    PR NEWSWIRE
    19 Jun 2024
    Share Share
    Medivir to Present Fostrox + Lenvima Data in HCC at ESMO GI
    Medivir to Present Fostrox + Lenvima Data in HCC at ESMO GI

    29 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/medivir-to-present-data-for-the-combination-of-fostrox--lenvima-in-hcc-at-esmo-gi-302129837.html

    PR NEWSWIRE
    29 Apr 2024
    Share Share
    Medivir presents data on additive activity of fostrox with Lenvima or sorafenib
    Medivir presents data on additive activity of fostrox with Lenvima or sorafenib

    07 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/medivir-presents-data-on-additive-activity-of-fostrox-in-combination-with-lenvima-or-sorafenib-in-non-clinical-tumor-models-at-ilca-301920306.html

    PR NEWSWIRE
    07 Sep 2023
    Share Share
    Medivir reports promising interim data
    Medivir reports promising interim data

    04 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/medivir-reports-promising-interim-data-including-a-first-complete-response-in-phase-1b2a-hcc-study-with-fostrox-in-combination-with-lenvima-301916719.html

    PR NEWSWIRE
    04 Sep 2023
    Share Share